Core Insights - AstraZeneca reported total revenue of $58.739 billion for the year 2025, reflecting an 8% year-over-year growth at constant exchange rates. Core earnings per share reached $9.16, marking an 11% increase compared to the previous year [1]. Business Performance - The oncology segment generated $25.6 billion in revenue, a 14% increase year-over-year, accounting for 44% of total revenue. Key products include Tagrisso (osimertinib) with sales of $7.254 billion, up 10%, and Imfinzi (durvalumab) with sales of $6.063 billion, showing a significant growth of 28%. Revenue from China reached $6.654 billion, a 4% increase, representing 11% of total revenue [2]. Project Development - In 2025, the company announced positive results from 16 Phase III clinical trials and currently has 16 blockbuster drugs. It is expected to disclose over 20 Phase III trial results in 2026, with more than 100 ongoing Phase III clinical trials [3]. Future Outlook - The company anticipates mid-to-high single-digit percentage growth in total revenue for 2026, with core earnings per share expected to grow in the low double-digit percentage range. Additionally, AstraZeneca plans to invest over 100 billion RMB in China from now until 2030 to expand its presence in drug manufacturing and research and development [4].